B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion
Abstract
The B7 family members B7-1 and B7-2 interact with CD28 and constitute an essential T-cell co-stimulatory pathway in the initiation of antigen-specific humoral and cell-mediated immune response. Here, we describe a third member of the B7 family, called B7-H1 that does not bind CD28, cytotoxic T-lymphocyte A4 or ICOS (inducible co-stimulator). Ligation of B7-H1 co-stimulated T-cell responses to polyclonal stimuli and allogeneic antigens, and preferentially stimulated the production of interleukin-10. Interleukin-2, although produced in small amounts, was required for the effect of B7-H1 co-stimulation. Our studies thus define a previously unknown co-stimulatory molecule that may be involved in the negative regulation of cell-mediated immune responses.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PD-L1 ligation inhibits migration and proliferation of T cells, thereby restricting tumour cell killing.
“Therefore, PD-L1 ligation is known to inhibit migration and proliferation of T cell, thereby restricting tumour cell killing (Figure 1) [55].”
From Immune Checkpoint Inhibitors in Cancer Therapy (2022) · cites this paper as [55]
Cited by
Sorted by citations
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · see citing works
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works
“All squamous type All doses 13 1 8 (0-36) ND 3 23 (5-54) 43 (15-71)”
InfluentialHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · see citing works
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · see citing works
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025 · see citing works
Self-citationImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · see citing works
PD-L1 expression as a predictive biomarker in cancer immunotherapy
Patel, S. P., & Kurzrock, R. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0983 · Cited by 2,291 · see citing works
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057 · see citing works
Inhibitory B7-family molecules in the tumour microenvironment
Zou, W., & Chen, L. (2008) · Nature Reviews Immunology · doi:10.1038/nri2326 · Cited by 1,608 · see citing works
Self-citationImmune Checkpoint Inhibitors in Cancer Therapy
Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works
Hamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378 · see citing works
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · see citing works
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314 · see citing works
Self-citationYokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works
Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity
Hirano, F., Kaneko, K., Tamura, H., Dong, H., Wang, S., Ichikawa, M., Rietz, C., Flies, D. B., Lau, J. S., Zhu, G., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.1089.65.3 · Cited by 1,018 · see citing works
Self-citationBrown, J. A., Dorfman, D. M., Ma, F.-R., Sullivan, E. L., Munoz, O., Wood, C. R., Greenfield, E. A., & Freeman, G. J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.3.1257 · Cited by 968 · see citing works
Nomi, T., Sho, M., Akahori, T., Hamada, K., Kubo, A., Kanehiro, H., Nakamura, S., Enomoto, K., Yagita, H., Azuma, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2746 · Cited by 889 · see citing works
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · see citing works
A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing
Pan, D., Kobayashi, A., Jiang, P., Ferrari de Andrade, L., Tay, R. E., Luoma, A. M., Tsoucas, D., Qiu, X., Lim, K., Rao, P., et al. (2018) · Science · doi:10.1126/science.aao1710 · Cited by 852 · see citing works
Thompson, R. H., Kuntz, S. M., Leibovich, B. C., Dong, H., Lohse, C. M., Webster, W. S., Sengupta, S., Frank, I., Parker, A. S., Zincke, H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4303 · Cited by 869 · see citing works
Self-citationOhigashi, Y., Sho, M., Yamada, Y., Tsurui, Y., Hamada, K., Ikeda, N., Mizuno, T., Yoriki, R., Kashizuka, H., Yane, K., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1469 · Cited by 796 · see citing works
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · see citing works
Thompson, R. H., Gillett, M. D., Cheville, J. C., Lohse, C. M., Dong, H., Webster, W. S., Krejci, K. G., Lobo, J. R., Sengupta, S., Chen, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406351101 · Cited by 776 · see citing works
Self-citationThe PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606 · see citing works
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589 · see citing works
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576 · see citing works
Groeger, S., & Meyle, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00208 · Cited by 473 · see citing works
Nakanishi, J., Wada, Y., Matsumoto, K., Azuma, M., Kikuchi, K., & Ueda, S. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-006-0266-z · Cited by 473 · see citing works
Role of the PD-1 pathway in the immune response
Riella, L. V., Paterson, A. M., Sharpe, A. H., & Chandraker, A. (2012) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2012.04224.x · Cited by 444 · see citing works
“PD-1 has two ligands, PD-L1 (B7H1; CD274) (4) and PD-L2 (B7-DC; CD273) (5,6), both of which have Ig-V-like and Ig-C-like extracellular domains and a short intracellular domain.”
BackgroundInman, B. A., Sebo, T. J., Frigola, X., Dong, H., Bergstralh, E. J., Frank, I., Fradet, Y., Lacombe, L., & Kwon, E. D. (2007) · Cancer · doi:10.1002/cncr.22588 · Cited by 438 · see citing works
Self-citationZhao, Y., Lee, C. K., Lin, C.-H., Gassen, R. B., Xu, X., Huang, Z., Xiao, C., Bonorino, C., Lu, L.-F., Bui, J. D., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.11.003 · Cited by 383 · see citing works
Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709802104 · Cited by 401 · see citing works
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420 · see citing works
Immune modulation by mesenchymal stem cells
Rasmusson, I. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2006.03.019 · Cited by 374 · see citing works
Mühlbauer, M., Fleck, M., Schütz, C., Weiss, T., Froh, M., Blank, C., Schölmerich, J., & Hellerbrand, C. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2006.05.007 · Cited by 378 · see citing works
Murine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368 · see citing works
PD-1 is a novel regulator of human B-cell activation
Thibult, M.-L., Mamessier, E., Gertner-Dardenne, J., Pastor, S., Just-Landi, S., Xerri, L., Chetaille, B., & Olive, D. (2013) · International Immunology · doi:10.1093/intimm/dxs098 · Cited by 365 · see citing works
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342 · see citing works
Bellucci, R., Martin, A., Bommarito, D., Wang, K., Hansen, S. H., Freeman, G. J., & Ritz, J. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008824 · Cited by 307 · see citing works
Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma
Görgün, G., Samur, M. K., Cowens, K. B., Paula, S., Bianchi, G., Anderson, J. E., White, R. E., Singh, A., Ohguchi, H., Suzuki, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0200 · Cited by 309 · see citing works
Inhibition of T–Cell Responses by Hepatic Stellate Cells Via B7–H1-Mediated T–Cell Apoptosis in Mice
Yu, M., Chen, C., Liang, X., Wang, L., Gandhi, C. R., Fung, J. J., Lu, L., & Qian, S. (2004) · Hepatology · doi:10.1002/hep.20488 · Cited by 301 · see citing works
Blockade of PD‐L1 (B7‐H1) augments human tumor‐specific T cell responses <i>in vitro</i>
Blank, C., Kuball, J., Voelkl, S., Wiendl, H., Becker, B., Walter, B., Majdic, O., Gajewski, T. F., Theobald, M., Andreesen, R., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21775 · Cited by 297 · see citing works
Diehl, L., Schurich, A., Grochtmann, R., Hegenbarth, S., Chen, L., & Knolle, P. A. (2008) · Hepatology · doi:10.1002/hep.21965 · Cited by 291 · see citing works
Self-citationSanthakumar, V., Aradi, I., & Soltesz, I. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00777.2004 · Cited by 262 · see citing works
Nazareth, M. R., Broderick, L., Simpson-Abelson, M. R., Kelleher, R. J., Yokota, S. J., & Bankert, R. B. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.9.5552 · Cited by 259 · see citing works
Wang, G.-Z., Zhang, L., Zhao, X.-C., Gao, S.-H., Qu, L.-W., Yu, H., Fang, W.-F., Zhou, Y.-C., Liang, F., Zhang, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08887-7 · Cited by 213 · see citing works
B7-H1-Induced Apoptosis as a Mechanism of Immune Privilege of Corneal Allografts
Hori, J., Wang, M., Miyashita, M., Tanemoto, K., Takahashi, H., Takemori, T., Okumura, K., Yagita, H., & Azuma, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.5928 · Cited by 208 · see citing works
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189 · see citing works
Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169 · see citing works
Yin–Yang of costimulation: crucial controls of immune tolerance and function
Nurieva, R. I., Liu, X., & Dong, C. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00769.x · Cited by 157 · see citing works
In Vivo Immune Modulatory Activity of Hepatic Stellate Cells in Mice
Chen, C.-H., Kuo, L.-M., Chang, Y., Wu, W., Goldbach, C., Ross, M. A., Stolz, D. B., Chen, L., Fung, J. J., Lu, L., et al. (2006) · Hepatology · doi:10.1002/hep.21379 · Cited by 154 · see citing works
Self-citationSeifert, A. M., Zeng, S., Zhang, J. Q., Kim, T. S., Cohen, N. A., Beckman, M. J., Medina, B. D., Maltbaek, J. H., Loo, J. K., Crawley, M. H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1163 · Cited by 149 · see citing works
Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells
Gray, C. P., Arosio, P., & Hersey, P. (2002) · Blood · doi:10.1182/blood.v99.9.3326 · Cited by 118 · see citing works
The deubiquitinase USP22 regulates PD-L1 degradation in human cancer cells
Wang, Y., Sun, Q., Mu, N., Sun, X., Wang, Y., Fan, S., Su, L., & Liu, X. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00612-y · Cited by 124 · see citing works
ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation
Wu, Y., Zhang, C., Liu, X., He, Z., Shan, B., Zeng, Q., Zhao, Q., Zhu, H., Liao, H., Cen, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22467-8 · Cited by 117 · see citing works
PD-1 regulates extrathymic regulatory T-cell differentiation
Chen, X., Fosco, D., Kline, D. E., Meng, L., Nishi, S., Savage, P. A., & Kline, J. (2014) · European Journal of Immunology · doi:10.1002/eji.201344423 · Cited by 107 · see citing works
Exosomal PD‐L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Zhou, K., Guo, S., Li, F., Sun, Q., & Liang, G. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.569219 · Cited by 99 · see citing works
Affinity purification mass spectrometry analysis of PD-1 uncovers SAP as a new checkpoint inhibitor
Peled, M., Tocheva, A. S., Sandigursky, S., Nayak, S., Philips, E. A., Nichols, K. E., Strazza, M., Azoulay-Alfaguter, I., Askenazi, M., Neel, B. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710437115 · Cited by 87 · see citing works
Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer
Saito, H., Kuroda, H., Matsunaga, T., Osaki, T., & Ikeguchi, M. (2013) · Journal of Surgical Oncology · doi:10.1002/jso.23281 · Cited by 94 · see citing works
Kim, I., Mlsna, L. M., Yoon, S., Le, B., Yu, S., Xu, D., & Koh, S. (2015) · Brain and Behavior · doi:10.1002/brb3.403 · Cited by 91 · see citing works
Phase Ib/II Study of Pembrolizumab and Pegylated-Interferon Alfa-2b in Advanced Melanoma
Davar, D., Wang, H., Chauvin, J.-M., Pagliano, O., Fourcade, J. J., Ka, M., Menna, C., Rose, A., Sander, C., Borhani, A. A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00632 · Cited by 86 · see citing works
Febrile seizures and mechanisms of epileptogenesis: insights from an animal model
Bender, R. A., Dubé, C., & Baram, T. Z. (2004) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4757-6376-8_15 · Cited by 83 · see citing works
Liu, J., Peng, X., Yang, S., Li, X., Huang, M., Wei, S., Zhang, S., He, G., Zheng, H., Fan, Q., et al. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-021-00816-w · Cited by 75 · see citing works
Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71 · see citing works
Ge, W., Ma, X., Li, X., Wang, Y., Li, C., Meng, H., Liu, X., Yu, Z., You, S., & Qiu, L. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.01.007 · Cited by 44 · see citing works
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40 · see citing works
Peptide‐based targeted therapeutics and apoptosis imaging probes for cancer therapy
Vadevoo, S. M. P., Gurung, S., Khan, F., Haque, M. E., Gunassekaran, G. R., Chi, L., Permpoon, U., & Lee, B. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01125-0 · Cited by 38 · see citing works
- Authors
- Dong, H., Zhu, G., Tamada, K., & Chen, L.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Chen, Lieping
- Venue
- Nature Medicine
- Published
- 1999-12
- Volume
- 5
- Issue
- 12
- Pages
- 1365-1369
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W1568317937
- Cited by
- 2,496
- References
- 0
- Citations by year
- 2026: 59 · 2025: 83 · 2024: 110 · 2023: 116 · 2022: 126 · 2021: 150 · 2020: 154 · 2019: 162 · 2018: 159 · 2017: 150 · 2016: 131 · 2015: 117 · 2014: 85 · 2013: 95 · 2012: 76
- FWCI
- 13.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA79915, CA 09127, R01CA079915)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- PD-L1, B7 family, T cell costimulation, IL-10, interleukin-2, CD28, ICOS, CTLA-4, T cell proliferation, negative regulation of immune response, allogeneic antigens
- MeSH terms
- Amino Acid Sequence, Animals, Cell Line, Cloning, Molecular, Humans, Immunity, Cellular, Interleukin-2, Lymphocyte Activation, Molecular Sequence Data, Recombinant Proteins, T-Lymphocytes, Transfection, Gene Expression, Interleukin-10, Sequence Homology, Amino Acid, DNA, Complementary, B7-1 Antigen, In Vitro Techniques
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
